Zeosa (norethindrone and ethinyl estradiol tablets USP, (chewable), 0.4 mg/0.035 mg, and ferrous ...

FDA Drug Recall #D-1397-2012 — Class II — May 2, 2012

Recall Summary

Recall Number D-1397-2012
Classification Class II — Moderate risk
Date Initiated May 2, 2012
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Teva Pharmaceuticals USA, Inc.
Location Sellersville, PA
Product Type Drugs
Quantity 100,761 cartons

Product Description

Zeosa (norethindrone and ethinyl estradiol tablets USP, (chewable), 0.4 mg/0.035 mg, and ferrous fumarate tablets USP, (chewable) 75 mg), 3 Blister Cards, 28 Tablets Each, Rx only, TEVA Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-2090-28 and 0093-2090-58, cartons containing three (3) individual blister packs

Reason for Recall

Impurities/Degradation: This recall is being carried out due to the potential for some lots not meeting impurity specifications.

Distribution Pattern

Nationwide

Lot / Code Information

Lot #'s 33800226A, Exp 7/2012; 33800333A, Exp 10/2012; 33800870A, Exp 10/2012; 33802533A, Exp 4/2013; and 33802720A, Exp 8/2013

Other Recalls from Teva Pharmaceuticals USA, Inc.

Recall # Classification Product Date
D-0518-2020 Class II Valganciclovir Hydrochloride for Oral Solution,... Nov 4, 2019
D-747-2014 Class III Fluconazole Oral Suspension, 10 mg/mL, 35 ml bo... Nov 14, 2013
D-1061-2014 Class II Valacyclovir Hydrochloride Tablets, 1 g, 30 cou... Nov 8, 2013
D-928-2013 Class II CARBOplatin Injection, 600 mg/60ml, MultiDose, ... Aug 13, 2013
D-924-2013 Class II Propranolol Hydrochloride Tablets, USP, 10 mg, ... Aug 6, 2013

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.